SUDA Licenses a Novel iNKT ( invariant Natural Killer T) Cell Therapy Platform from Imperial College London
- SUDA obtains a global, exclusive Licence from Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment.
- Its a platform technology .The iNKT cell platform can be used in conjunction with multiple chimeric antigen receptors (CARs) to target blood cancers. iNKT cells are expected to be suitable for off-the-shelf dosing, as one healthy donor can supply cells to treat many patients.
- CAR-iNKT cells have been shown to outperform conventional CART cell therapies in preclinical studies.
Pre-clinical studies show that:
▪ CAR-iNKT cells work more efficiently than conventional cell therapies
▪ CAR-iNKT cells outperform CAR-T cells, rapidly clearing the cancer cells and increasing the number of surviving animals by 1.5x when the CD1d protein is on the surface of cancer cells.
▪ CAR-iNKT cells can result in a remission without additional treatment
▪ Additional CARs could be added to the iNKT cells, potentially enhancing their activity
In vivo anti-tumour activity of CAR19-iNKT after three days
▪ Tumour cells expressing CD1d were intravenously delivered into mice
▪ Mice were treated with:
▪ Nothing (PBS)
▪ Unmodified T cells (T)
▪ Unmodified iNKT cells (iNKT)
▪ CAR19-T cells
▪ CAR19-iNKT cells
▪ After three days, all cancer cells in the iNKT treated mice were eradicated
▪ Cancer cells persisted with all other treatments
▪ CAR19-iNKT cells display swift action and memory-like effect
Extremely exciting results from animal models
CAR19-iNKT Cells: Superior Animal Survival After 90 days
After 90 days only mice treated with CAR19-T cells or CAR19-iNKT remained alive
1.5x more mice treated with CAR19-iNKT cells remained alive after 90 days relative to CAR19-T cells
As you can see from the results above , Overall survival of animal models was almost 100 % After 10 days
In vivo anti-tumour activity of CAR19- iNKT cells following relapse
▪ Tumour cells expressing CD1d were intravenously delivered into mice
▪ Four mice treated with CAR19-iNKT cells had the cancer return to the brain
▪ In all four mice, the cancer was eliminated a second time with no additional dosing
▪ This provides evidence that CAR19- iNKT cells can survive and continue to protect against cancer cells in vivo
iNKT platform technology can also be potentially use to produce an ‘off-the-shelf’ product
iNKT cells have been shown to be protective against acute graft-versus host disease (GVHD).
As such, the therapy may be produced from a healthy donor and delivered to many patients, potentially resulting in a more effective product.
SUD is lead by Mr Paul Hopper , who is a serial achiever in Bio Medical Healthcare Sector
Mr. Hopper Founded IMU Mcap which is trading at 1.78 Billion Mcap
He Sold viralytics for 500 mil
He is a founder of PTX trading at 125 Mil Mcap
He is a founder of BioScience Oncology which was acquired by Scopus Biotech
He was a founder of Glioblast which was merged into KZA trading at 178 Mil Mcap
He is a founder of newly listed CHM trading at 97.6 Mil Mcap
And cheapest of all , Mr. Baker is the chairman of SUD trading at 10 Mil EV and I am extremely confident Mr. Hopper will lead SUD team to success with this new acquisition !
Some recent deals in this sector are attracting a lot of investments
Athenex to Acquired Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform for Total potential consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones . Kurr is also an early stage iNKT cell therapy company
https://ir.athenex.com/news-releases/news-release-details/athenex-acquire-kuur-therapeutics-expand-cell-therapy
Appia Bio raised $52 Million Series A Financing in MAY 2021 . Appia Bio is a pre clinical iNKT cell therapy platform company.
https://www.prnewswire.com/news-releases/appia-bio-launches-with-52-million-series-a-financing-and-establishes-scientific-advisory-board-301287685.html
IMO this deal is a game changer for SUDA and its shareholders . I can understand the frustration of long-term investors of SUD and I must admit that I have also invested in SUD a year back and it has been a painful hold + the opportunity cost but I am extremely pleased with this deal and IMO this new deal will make our wait a worthwhile !
I will be a buyer in SUD under 5c ( 25 mil Mcap , 8 Mil Cash )
In medium term my realistic target for SUD is 20c ( 100 mil Mcap ) and In long term post completion of phase 1 , IMO it can get bluesky valuations !
Also please note it's not a one trick pony ,It's a platform tech and can generate pipeline of multiple programs !
Please DYOR
ALL IMO
Bhavdip
- Forums
- ASX - By Stock
- THE NEW BEGINNING
SUDA Licenses a Novel iNKT ( invariant Natural Killer T) Cell...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALA (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $126.0M |
Open | High | Low | Value | Volume |
12.0¢ | 12.5¢ | 11.5¢ | $57.73K | 487.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 482081 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 387904 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 482081 | 0.115 |
9 | 377425 | 0.110 |
9 | 378608 | 0.105 |
16 | 533050 | 0.100 |
3 | 16047 | 0.099 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 387904 | 4 |
0.125 | 309271 | 4 |
0.130 | 769203 | 5 |
0.135 | 120779 | 2 |
0.140 | 539388 | 10 |
Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
Last
11.8¢ |
  |
Change
-0.005 ( 6.00 %) |
|||
Open | High | Low | Volume | ||
12.5¢ | 12.5¢ | 11.5¢ | 976157 | ||
Last updated 15.52pm 14/05/2024 ? |
Featured News
ALA (ASX) Chart |